The genetic architecture of refractory epilepsy
Epilepsy affects approximately 1% of the global population, and 30–40% of those patients remain refractory to all available pharmacotherapy—a treatment gap that has sustained decades of investment in mechanistically novel antiseizure agents. The core pathophysiological model documented across patent filings and academic literature is consistent: epilepsy arises from disrupted excitatory/inhibitory neuronal balance, most often traceable to mutations in voltage-gated ion channel genes.
Among specific molecular targets, SCN1A—encoding the Nav1.1 voltage-gated sodium channel subunit—is the highest-frequency target across retrieved patent and literature results, appearing in filings from Praxis Precision Medicines, the Allen Institute, the Broad Institute, and Bionomics, as well as in multiple academic publications. SCN1A haploinsufficiency in GABAergic inhibitory interneurons is established as the primary pathogenic mechanism of Dravet syndrome (DS): loss of Nav1.1 function impairs the firing capacity of parvalbumin-positive (PV+) interneurons, releasing uncontrolled excitatory neuronal activity.
SCN1A haploinsufficiency in GABAergic inhibitory interneurons is the primary pathogenic mechanism of Dravet syndrome. Loss of Nav1.1 function impairs parvalbumin-positive interneuron firing capacity, releasing uncontrolled excitatory neuronal activity.
SCN2A and SCN8A are also explicitly targeted in retrieved results. Praxis Precision Medicines describes de novo gain-of-function or loss-of-function mutations in these genes as causes of developmental and epileptic encephalopathy (DEE). A pharmacogenetic filing (BAUM, 2009, WO) discloses that specific SCN2A alleles—IVS7-31A>G and R19K—confer resistance to all classes of antiepileptic drugs (AEDs) or specifically to sodium channel blockers, establishing a precision medicine rationale for genotype-guided therapy selection.
KCNT1, encoding sodium-activated potassium Slack channels, emerges as a critical secondary target. Gain-of-function KCNT1 mutations are linked to epilepsy of infancy with migrating focal seizures (EIMFS), autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), West syndrome, Ohtahara syndrome, and Lennox-Gastaut syndrome. The CDKL5 gene is highlighted in Marinus Pharmaceuticals filings as a genetic driver of pediatric epileptic encephalopathy, while additional targets documented in retrieved results include EFHC1, PRRT2, miR-335-5p, miR-128, and PDE4.
This analysis is derived from a targeted set of patent and literature records retrieved across focused searches. It represents a snapshot of innovation signals within this dataset only and should not be interpreted as a comprehensive view of the full clinical pipeline or regulatory landscape.
Sodium channel modulators: blockers, activators, and the INaL opportunity
Sodium channel modulation is the most represented therapeutic modality in the retrieved dataset, with two mechanistically distinct subclasses documented—traditional state-dependent blockers and an emerging class of channel activators that inverts the conventional pharmacological logic.
State-dependent blockers and the drug-resistance problem
Eslicarbazepine acetate (BIA 2-093), developed by BIAL-Portela & C.A. S.A., is covered across multiple jurisdictions including WO, IL, JP, CA, BR, MX, and US—a multi-decade, multi-geography patent estate reflecting commercial lifecycle management. Retrieved filings describe it as a voltage-gated sodium channel inhibitor with a mechanistically important distinction: it is not a substrate for P-glycoprotein (P-gp) or multidrug resistance protein (MRP) efflux transporters. In drug-resistant epilepsy, overexpression of these transporters at the blood-brain barrier is a key mechanism reducing CNS exposure to conventional AEDs. The BIAL filings include human clinical pharmacokinetic data (Cmax, AUC, t½ in healthy elderly and young subjects), confirming clinical-stage exposure data.
Eslicarbazepine acetate (BIA 2-093) is uniquely not a substrate for P-glycoprotein (P-gp) or multidrug resistance protein (MRP) efflux transporters, offering a mechanistic advantage in drug-resistant epilepsy where transporter overexpression reduces brain exposure to conventional antiseizure drugs.
Praxis Precision Medicines covers eleclazine and a broader compound series targeting abnormal late/persistent sodium current (INaL) in SCN1A/SCN2A/SCN8A-associated DEE and Dravet syndrome. This patent family—with filings across WO (2018, 2019), US (2020), CA (2023), BR (2025), and CN (2025)—is the most geographically expansive in the retrieved dataset, consistent with clinical-stage or late-preclinical asset protection.
Nav1.1 activators: a mechanistic reversal
Xenon Pharmaceuticals Inc. has filed multiple patents on pyridine derivatives and heteroaryl sulfonamide compounds as voltage-gated sodium channel activators for epilepsy—a notable mechanistic departure from conventional AED pharmacology. Rather than blocking sodium channels, these compounds pharmacologically restore Nav1.1 activity, directly addressing the loss-of-function deficit underlying Dravet syndrome. Recent CN filings (2024–2025) indicate active prosecution in the Chinese market. As documented in the patent literature, standard sodium channel blockers may be contraindicated or paradoxically harmful in loss-of-function SCN1A channelopathies, making the activator concept a potentially differentiated position in the treatment landscape, according to analysis from PatSnap‘s innovation intelligence platform.
“Nav1.1 activators represent a mechanistic departure from conventional AED pharmacology—pharmacologically restoring channel activity rather than blocking it, directly targeting the loss-of-function deficit in Dravet syndrome.”
Explore the full sodium channel modulator patent landscape with PatSnap Eureka’s AI-powered search.
Search Epilepsy Patents in PatSnap Eureka →Potassium channel strategies: opening, closing, and KCNT1 inhibition
Potassium channel modulation in epilepsy encompasses two mechanistically opposite strategies documented in the retrieved dataset: channel openers that reduce neuronal excitability by facilitating potassium efflux, and targeted inhibitors that counteract pathological gain-of-function mutations in specific channel subtypes.
Channel openers (KCOs)
Valeant Pharmaceuticals International holds a patent on 4-(N-azacycloalkyl) anilide derivatives as modulators of voltage-gated potassium channels with explicit utility in seizure disorders. ERG (ether-à-go-go-related gene) channel openers are described in a WO filing assigned to Christophersen as reducing neuronal excitability by facilitating potassium efflux, proposed for hyperexcitability-related neuronal diseases including epilepsy. Ritigabine (ezogabine) is cited as a reference KCO in background sections of multiple retrieved patents from Ovid Therapeutics and Praxis. Otsuka Pharmaceutical Co., Ltd. has filed on heterocyclic compounds that include Kv3.1/Kv3.2 channel modulators among their mechanisms of action for epilepsy treatment, according to filings retrieved via PatSnap Eureka.
KCNT1 inhibitors: targeting gain-of-function overactivity
Praxis Precision Medicines has filed multiple patents (IL 2022, EP 2025) on small-molecule inhibitors of KCNT1 (Slack channels) that specifically target gain-of-function mutations. This represents an inhibitory potassium channel strategy—counteracting pathological channel overactivity rather than enhancing potassium efflux. The disease rationale is mechanistically distinct: KCNT1 gain-of-function mutations paradoxically increase neuronal excitability by disrupting normal sodium-activated feedback regulation. Target indications include EIMFS, ADNFLE, and West syndrome. Retrieved patent texts describe the compounds and disease rationale but do not contain clinical outcome data, placing development stage at preclinical/early IND-enabling.
KCNT1 gain-of-function mutations drive sodium-activated potassium channel overactivity that paradoxically increases neuronal excitability, causing epilepsy of infancy with migrating focal seizures (EIMFS), autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), West syndrome, Ohtahara syndrome, and Lennox-Gastaut syndrome. Praxis Precision Medicines holds the concentrated IP position in KCNT1 inhibition across IL (2022) and EP (2025) jurisdictions.
KCNT1 inhibition for EIMFS and ADNFLE represents an early-stage asset with concentrated IP in a single assignee (Praxis Precision Medicines) and no approved pharmacogenomically matched therapy—a potentially defensible orphan disease position with high unmet medical need.
Gene therapy and RNA approaches: from proof-of-concept to platform
Gene therapy and RNA-based strategies constitute a substantial and growing cluster in the retrieved dataset, predominantly targeting Dravet syndrome through SCN1A rescue via four distinct biological mechanisms. According to WHO and published research, rare genetic epilepsies represent a priority area for advanced therapy medicinal products due to their severity and the absence of approved disease-modifying treatments.
AAV-mediated gene delivery
Allen Institute filings (CA 2019, US 2021, US 2025) describe selective AAV-based rescue of Nav1.1 function specifically in inhibitory neurons, exploiting cell-type-specific promoters to avoid delivery to excitatory neurons—a critical safety consideration given that Nav1.1 activation in excitatory neurons could be proconvulsant. The Allen Institute filings are supported by NIH federal funding (grant RF1MH114126), indicating publicly subsidised translational research with commercial IP claims. The Broad Institute (IL, 2021) covers rAAV vectors carrying SCN1A-encoding polynucleotides, Gq-DREADD-encoding polynucleotides, or PSAM-encoding polynucleotides, all restricted to PV-expressing GABAergic interneurons via enhancer sequences. Trames Bio, Inc. (IL, 2023) discloses AAV capsid engineering combined with engineered ligand-gated ion channels for focal epilepsy.
CRISPR/dCas9 transcriptional activation
A 2020 study by Colasante et al. demonstrated that dCas9-mediated Scn1a gene activation restored inhibitory interneuron excitability and attenuated seizures in a Dravet syndrome mouse model—providing preclinical proof-of-concept for gene activation as opposed to gene replacement. This approach, published in academic literature and retrievable via PatSnap Eureka, is distinct from AAV delivery in that it activates the endogenous gene rather than introducing an exogenous copy, potentially preserving native regulatory control.
Chemogenetics (DREADD)
UCL Business PLC holds an active international patent family (WO 2015, US 2016, EP 2017, ES 2020) on the combined use of a DREADD-encoding vector and an exogenous agonist (clozapine-N-oxide or equivalent) to reversibly suppress neuronal excitability at seizure foci. A 2019 academic abstract from Ghent University/KU Leuven documents long-term chemogenetic seizure suppression in a temporal lobe epilepsy mouse model. UCL’s DREADD patent is active but does not contain clinical trial data in the retrieved text; this remains a preclinical approach as of the dataset snapshot.
MicroRNA modulation
Royal College of Surgeons in Ireland holds a patent family (WO 2023, US 2025) on miR-335-5p modulators delivered to the brain for sodium channelopathies including epilepsy. The proposed mechanism is that miR-335-5p modulates expression of voltage-gated sodium channel genes; upregulation could suppress aberrant channel activity. Rockefeller University (AU 2020, CA 2025) covers miR-128 upregulation as a strategy to reduce neuronal excitability and prevent epilepsy development, with increased miR-128 expression reducing seizure susceptibility in preclinical models. As noted by NIH-funded researchers, microRNA-based approaches represent an upstream regulatory layer that could complement direct channel-targeting pharmacology.
A 2020 study (Colasante et al.) demonstrated that dCas9-mediated Scn1a gene activation restored inhibitory interneuron excitability and attenuated seizures in a Dravet syndrome mouse model, providing preclinical proof-of-concept for transcriptional gene activation as a Dravet syndrome therapy distinct from AAV gene replacement.
Map the full gene therapy patent landscape for Dravet syndrome and rare epilepsies in PatSnap Eureka.
Explore Gene Therapy Patents in PatSnap Eureka →Combination strategies and the precision medicine pivot
Retrieved results signal several combination strategies and emerging therapeutic directions that point toward a precision medicine model—moving away from population-level AED trials toward genotype-stratified development programs.
The Praxis ion channel modulator filings (CN 2025) explicitly enumerate combinations with brivaracetam, carbamazepine, clobazam, eslicarbazepine, lamotrigine, lacosamide, and cannabidiol, suggesting that late sodium current modulators are being developed with combination positioning in mind from the outset. The Broad Institute rAAV filings cover both SCN1A gene restoration and Gq-DREADD expression within the same vector framework—a dual-mechanism approach combining structural restoration of interneuron sodium channel function with pharmacologically regulable inhibitory silencing.
Eisai R&D Management Co., Ltd. (WO 2009, EP 2010) explicitly claims AMPA receptor antagonist plus multiple AED combination regimens, supported by evidence that AMPA receptor plasticity sustains status epilepticus. Janssen Pharmaceutica NV (AU 2023) claims combinations of mGluR2 positive allosteric modulators with synaptic vesicle protein 2A (SV2A) ligands such as levetiracetam analogs, citing antiepileptogenic activity in kindling models. A 2025 WO filing (WINZER-SERHAN) proposes α7 nicotinic acetylcholine receptor (α7-nAChR) activators, alone or combined with established AEDs, specifically for post-traumatic epileptogenesis prevention—a disease-modification angle absent from most other retrieved filings.
The pharmacogenomic stratification signal is consistent across the dataset: the SCN2A polymorphism filing (BAUM, 2009) establishes that specific alleles predict pan-class AED resistance; Marinus Pharmaceuticals targets CDKL5 mutation patients specifically with ganaxolone, citing low endogenous neurosteroid levels as an addressable deficit. As noted in EMA guidance on rare disease drug development, genotype-based patient selection is increasingly recognised as a means of improving clinical success rates for mechanisms that have historically failed in unselected epilepsy populations.
“Pharmacogenomic stratification of AED response—documented through SCN2A polymorphisms and CDKL5 mutations—is emerging as a drug development enabler. Precision medicine trial designs incorporating genetic preselection may improve clinical success rates for novel mechanisms that have historically failed in unselected epilepsy populations.”
IP landscape: assignee concentration and freedom-to-operate signals
The epilepsy ion channel patent landscape is characterised by a small number of highly active assignees with overlapping claim territories—particularly in the Dravet syndrome/SCN1A space—alongside concentrated orphan disease positions in less-contested genetic subtypes.
Assignee profiles
Praxis Precision Medicines is the most prolific assignee in this dataset, with filings spanning sodium channel modulators (eleclazine/Formula I series), KCNT1 inhibitors, and neurological disorder treatment methods across WO, US, CA, BR, EP, and CN jurisdictions—an aggressive global IP strategy across multiple ion channel targets. BIAL-Portela & C.A. S.A. maintains a multi-jurisdictional, multi-decade estate on eslicarbazepine acetate across at least seven jurisdictions. Xenon Pharmaceuticals Inc. holds a coherent cluster on Nav1.1 activators with recent CN prosecution (2024–2025). Allen Institute holds a growing US patent family (2019–2025) on AAV-based Nav1.1 rescue in inhibitory neurons, supported by NIH federal funding.
Academic institutions with active IP include the Broad Institute (interneuron-specific rAAV vectors), UCL Business PLC (DREADD chemogenetics), Royal College of Surgeons in Ireland (miR-335-5p), and Rockefeller University (miR-128). These institutions represent potential licensing or collaboration targets for larger biopharma seeking platform gene therapy capabilities, as tracked through PatSnap‘s assignee analytics.
The strategic implication is clear: the Dravet syndrome/SCN1A haploinsufficiency space is therapeutically crowded at the IP level. Praxis Precision Medicines, Allen Institute, the Broad Institute, Xenon Pharmaceuticals, Royal College of Surgeons in Ireland, and UCL Business PLC all hold active or pending patents targeting Nav1.1 rescue through distinct modalities. Drug developers and IP strategists entering this space should map freedom-to-operate carefully across these overlapping claim landscapes, a task for which patent intelligence platforms such as those described by WIPO in its global IP reporting are well suited.